Business Wire

THETARAY

Share
ClearBank Selects ThetaRay AI Monitoring Tech to Accelerate Business Growth

ClearBank, the largest next-generation clearing and embedded banking platform in the UK, and ThetaRay, provider of AI-powered transaction monitoring technology, today announced they will collaborate in cloud-native anti-money laundering (AML) monitoring to protect ClearBank against financial crime with ThetaRay’s robust and industry-leading AI solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005168/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ClearBank logo

Through the agreement, ClearBank will transform its AML monitoring operations to a fully cloud-native program with ThetaRay’s SaaS SONAR AML solution. The cloud-native SONAR system will provide ClearBank the flexibility to scale and support faster and safer processing of increasing transaction volumes on its platform.

ClearBank is the first proven and fully regulated cloud-native clearing bank in the UK, operating with more than 200 financial institutions and fintech customers, 13 million accounts, and £3bn in balances.

“The ThetaRay AML system powered by artificial intelligence (AI) and machine learning technology will give us the edge that will enable us to win new financial partnerships and unlock the potential of our business model to bring positive and meaningful change for customers in the UK, Europe and beyond,” said Nigel Walder, Chief Operating Officer, ClearBank. “The ThetaRay risk-based analytical capabilities can detect hidden financial crime hidden within the data of transactions passing through complex financial networks, including known and unknown typologies.”

ClearBank selected ThetaRay as the best partner for its ability to deliver a SaaS solution with API-driven integration, scalability, and usability with an intuitive investigative tool for analysts for first-line analysis.

“We are honored to have a partner like ClearBank that is leading the banking innovation space by reducing costs and friction with cloud-native financial services. Our companies have great synergy, and we look forward to a long-term relationship to grow the financial industry,” said Mark Gazit, CEO of ThetaRay. “Our fully scalable SaaS solution empowers payment fintechs with operational benefits to achieve trusted global transactions without having to worry about the maintenance of additional infrastructure, while satisfying regulators, improving the customer experience, and quickly opening new revenue streams.”

ThetaRay’s award-winning SONAR solution is based on a proprietary form of AI, artificial intelligence intuition, that replaces human bias, giving the system the power to recognize anomalies and find unknowns outside of normal behavior, including completely new typologies. It enables fintechs and banks to implement a risk-based approach to effectively identify truly suspicious activity and create a full picture of customer identities, including across complex, cross-border transaction paths. This allows the rapid discovery of both known and unknown money laundering threats, and up to 99 percent reduction in false positives compared to rules-based solutions.

About ClearBank

ClearBank is a purpose-built clearing and embedded banking platform. Through its banking license and intelligent, robust technology solutions, ClearBank enables its partners to offer real-time payment and innovative banking services to their customers. ClearBank is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority (Financial Services Register number: 754568).

Visit www.clear.bank for more information.

About ThetaRay

ThetaRay's AI-powered SONAR transaction monitoring solution, based on “artificial intelligence intuition,” allows banks and fintechs to expand their business opportunities through safe and reliable cross-border payments. The groundbreaking solution also improves customer satisfaction, reduces compliance costs, and increases risk coverage. Financial organizations that rely on highly heterogeneous and complex ecosystems benefit greatly from ThetaRay's unmatchable low false positive and high detection rates.

Learn more at www.thetaray.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005168/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 08:30:00 CET | Press release

The GDC, established in LTTS’ Mobility segment, will strengthen PALFINGER’s localization roadmap and next-gen digital transformation initiatives L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, E

New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 08:10:00 CET | Press release

Cinemo and Futuresource Consulting’s research indicates consumer readiness for integrated audio environments, accelerating the shift from connected devices to a connected lifestyle. Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual

NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release

NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release

Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye